Published in Cancer Weekly, November 1st, 2005
Under the terms of the acquisition, which was approved by Guilford's shareholders, all shares of Guilford were exchanged for 5.3 million shares of MGI Pharma stock plus $53.9 million in cash, which represents $3.75 per Guilford share, as determined based on MGI Pharma's 5-day average stock price ending on September 25, 2005 (three days prior to the transaction closing...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.